A carbon-coated transition metal nanocomposite material includes carbon-coated transition metal particles having a core-shell structure. The shell layer of the core-shell structure is a graphitized carbon layer doped with oxygen and/or nitrogen, and the core of the core-shell structure is a transition metal nanoparticle. The nanocomposite material has a structure rich in mesopores, is an adsorption/catalyst material with excellent performance, can be used for catalyzing various hydrogenation reduction reactions, or used as a catalytic-oxidation catalyst useful for the treatment of volatile organic compounds in industrial exhaust gases.

A carbon-coated transition metal nanocomposite material includes carbon-coated transition metal particles having a core-shell structure. The shell layer of the core-shell structure is a graphitized carbon layer doped with oxygen and/or nitrogen, and the core of the core-shell structure is a transition metal nanoparticle. The nanocomposite material has a structure rich in mesopores, is an adsorption/catalyst material with excellent performance, can be used for catalyzing various hydrogenation reduction reactions, or used as a catalytic-oxidation catalyst useful for the treatment of volatile organic compounds in industrial exhaust gases.

The present invention relates to modulators of ATP-Binding Cassette (ABC) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

The present invention relates to modulators of ATP-Binding Cassette (ABC) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

The invention relates to a process for the preparation of a compound represented by formula (I) wherein X is selected from the group consisting of H, -halogen, linear or branched C1-C7 alkyl group, linear or branched C1-C5 alkoxy group, NO.sub.2 and CN and Y is a linear or branched C1-C7 alkyl group, comprising the steps of: 10 a) reacting a compound represented by formula (II) with a compound represented by (III) to obtain an intermediate product, wherein X is as defined with respect to formula (I), wherein Z is H, CH.sub.3 or C.sub.2H.sub.5, b) reacting the intermediate product of step a) with a compound represented by Y.sub.2SO.sub.4 (IV) wherein Y is as defined with respect to formula (I) to obtain a salt and c) hydrolyzing the salt of step b) to obtain the compound of formula (I).

##STR00001##

The invention relates to a process for the preparation of a compound represented by formula (I) wherein X is selected from the group consisting of H, -halogen, linear or branched C1-C7 alkyl group, linear or branched C1-C5 alkoxy group, NO.sub.2 and CN and Y is a linear or branched C1-C7 alkyl group, comprising the steps of: 10 a) reacting a compound represented by formula (II) with a compound represented by (III) to obtain an intermediate product, wherein X is as defined with respect to formula (I), wherein Z is H, CH.sub.3 or C.sub.2H.sub.5, b) reacting the intermediate product of step a) with a compound represented by Y.sub.2SO.sub.4 (IV) wherein Y is as defined with respect to formula (I) to obtain a salt and c) hydrolyzing the salt of step b) to obtain the compound of formula (I).

##STR00001##

The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

The invention relates to substituted adamantane compounds, pharmaceutical compositions thereof, processes for their preparation, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

A task is to provide a method for producing a polycyclic aromatic aminophenol compound through a reduced number of steps at a low cost with high safety. The method for producing a polycyclic aromatic aminophenol compound includes the step of reacting a compound represented by the general formula (1) below and an aromatic amino compound with each other: ##STR00001##
Wherein n represents an integer of 1 to 8, Ar represents a benzene ring optionally having a substituent, or a naphthalene ring optionally having a substituent, each of R.sup.1 and R.sup.2 independently represents a hydrogen atom, a hydrocarbon group having 1 to 6 carbon atoms and optionally having a substituent, or an aromatic group optionally having a substituent, and R.sup.3 represents a hydroxyl group, a methoxy group, or a halogen atom.

A task is to provide a method for producing a polycyclic aromatic aminophenol compound through a reduced number of steps at a low cost with high safety. The method for producing a polycyclic aromatic aminophenol compound includes the step of reacting a compound represented by the general formula (1) below and an aromatic amino compound with each other: ##STR00001##
Wherein n represents an integer of 1 to 8, Ar represents a benzene ring optionally having a substituent, or a naphthalene ring optionally having a substituent, each of R.sup.1 and R.sup.2 independently represents a hydrogen atom, a hydrocarbon group having 1 to 6 carbon atoms and optionally having a substituent, or an aromatic group optionally having a substituent, and R.sup.3 represents a hydroxyl group, a methoxy group, or a halogen atom.